Drugs / AMV564
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04128423 | Oct 2019 → Dec 2021 | — | Amphivena Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT03516591 | Jun 2018 → Jul 2020 | myelodysplastic syndrome | Amphivena Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03144245 | Mar 2017 → Jul 2020 | acute myeloid leukemia | Amphivena Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMV564 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03144245 ↗ |
| Known as | CNTO 3953 TANDAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297552 ↗ |
| Known as | CNTO-3953 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297552 ↗ |
| Known as | T-652 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297552 ↗ |
| Known as | Vixtimotamab | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297552 ↗ |
| Modality | Protein / enzyme biologic | “a CD33 x CD3 Tandem Diabody” NCT03144245 ↗ |
| Route | Intravenous | “AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing” NCT03144245 ↗ |
| Route | Subcutaneous | “AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing” NCT03144245 ↗ |
| Target | CD33 | “a CD33 x CD3 Tandem Diabody” NCT03144245 ↗ |